Can a simple blood test predict chemo side effects in brain cancer patients?

NCT ID NCT02617745

Completed Knowledge-focused Sponsor: Centre Henri Becquerel Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2 study looked at 244 glioblastoma patients to see if platelet counts during radiation and chemotherapy could predict who would develop dangerously low platelets later. The goal was to create a monitoring plan for high-risk patients. No new drug or treatment was tested.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors identify glioblastoma patients at risk for low platelets during standard treatment, allowing closer monitoring.
What could go wrong: This is an observational analysis of existing treatment, not a test of a new therapy. It may not lead to changes in care or improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma thrombocytopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Centre Henri Becquerel

Rouen, 76038, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.